Long-term Efficacy and Safety of the DUMON ST Hourglass Stent for Treatment of Post-Intubation or Tracheotomy Benign Tracheal Stenosis

The evidence of long-term efficacy and safety about the DUMON ST hourglass stent in the treatment of post-intubation or tracheotomy benign trachea stenosis (BTS) is limited. We retrospectively reviewed patients with post intubation or tracheotomy BTS who were treated with the hourglass stent at the First Affiliated Hospital of Chongqing Medical University between Jan 2023 and Dec 2023. The clinical data and bronchoscopic interventional procedures related information were collected and analyzed. Seventeen patients with BTS were included. Five (29.4%) patients had intubation-related stenosis, with an average duration of intubation of 2 weeks while 12 (70.6%) patients had tracheotomy-related stenosis, with an average duration of tracheotomy of 3 weeks. Nine patients (52.9%) were male and 8 (47.1%) were female. The overall success rate of stent deployment was 94.1% (16/17). Only one patient developed dyspnea immediately after the hourglass stent was deployed, and therefore a T-tube was placed instead. There were no peri-operative deaths related to the intervention. Stent displacement was seen in 5 out of 16 cases, but only one case experienced repeated displacement during the 12-month follow-up period. Of the 16 patients, 2 patients developed severe granuloma formation, resulting in repeated bronchoscopic resection. Retention of secretion was the most common complication (87.5%), but it was generally tolerated well. DUMON ST Hourglass Stent is an effective and safe way for treatment of post-intubation or tracheotomy benign tracheal stenosis , however, more evidence was needed.